Heterosubstituted pyridine derivatives as PDE4 inhibitors
申请人:Merck Frosst Canada & Co.
公开号:US06200993B1
公开(公告)日:2001-03-13
The invention encompasses the novel compound of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3′,5′-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE 4).
or a pharmaceutically acceptable salt or hydrate thereof.
The invention also encompasses pharmaceutical compositions and methods for treatment.